De-risking Therapeutic Development for Brain Disorders
Therapeutic development for brain disorders is the longest, costliest, and riskiest of all diseases, with only 6% of candidate therapies receiving FDA approval. At Inscopix, our goal is to de-risk and accelerate therapeutic development for neurological and psychiatric disorders by developing quantitative live preclinical assays that combine our advanced miniscope platform with deep mechanistic insights about the brain in health and disease.
Inscopix’s miniscope platform enables:
- Large scale imaging of neural activity at single-cell resolution and cell-type specificity during free behavior.
- Live measurements enabling intra-subject study design, higher statistical power and more data per animal behavior.
- Experimental access to all brain regions in mouse, rat, marmoset, and macaque.
- Easy integration with with EEG to inform biomarker translation to the clinic.
A Quantitative & Data Driven Approach to Preclinical Neurotherapeutic R&D
By targeting neural circuits, the Inscopix miniscope platform provides direct in vivo live readouts of disease progression and therapeutic intervention and empowers informed decision-making and more effective translation of preclinical animal data to human clinical trials.
Improved Pharmacodynamic Readouts
The Inscopix miniscope platform provides a powerful new tool for in vivo pharmacodynamic and circuit engagement readouts – plugging directly into ongoing efforts to profile and prioritize compounds in terms of PK/PD, target engagement, dosing and assessment of safety and off-target side effects.
Predictive Efficacy Assays
Over 50% of the candidates for CNS disorders fail due to a lack of clinical efficacy. Inscopix’s miniscope platform-based efficacy assays for screening novel therapeutics enable measurement and characterization of disease-related pathophysiology at the circuit level–and have proven to more accurately predict clinical efficacy than animal behavior and other measures.
Neural activity signatures in Parkinson's disease
Researchers from Stanford & Pfizer used state-of-the-art brain imaging technology, our miniature microscope-based platform nVista, to peer into a brain region called the striatum in a mouse model of Parkinson’s disease (PD). By monitoring activity in hundreds of neurons simultaneously in the living brain, they observed aberrations in striatal activity patterns that encode voluntary movement. The researchers then tested compounds like L-DOPA, the mainstay PD treatment, and other dopamine agonists that have proven to be less efficacious than L-DOPA in the clinic, and found significant correspondence between a compound's ability to correct the pathological striatal activity patterns and its clinical efficacy.
Our Biopharma Partners
Our Biopharma Partners
We collaborate with established biopharma companies and startups that are developing new therapeutic interventions for a wide range of complex neurological and psychiatric disorders such as Alzheimer’s Disease, Parkinson’s, treatment-resistant depression, and Autism Spectrum Disorders.
Partner with Inscopix
Inscopix blends the best of cutting-edge neurotechnology, a fast-paced startup environment, and a world-class team of neuroscientists, data scientists, and engineers. We seek external partnerships with companies that we can engage on a deep scientific and technological level to transform preclinical neuroscience R&D. You can partner with us in two ways:
- Establish the Inscopix platform in-house and our team will work closely with you to integrate it efficiently and successfully into your preclinical R&D programs.
- Collaborate with us through co-developed contract research studies and let our highly skilled team of experimental and computational Neuroscientists execute and deliver the data and insights you need to inform and advance your therapeutic development programs.
We would love to hear from you! If you are interested in collaborating with Inscopix, please send us a message below with non-confidential information.